Pfizer Investor Presentation — June 2020

Document content

Analyst and Investor Call to Review

Presentations of Hemophilia A Gene

Therapy at WFH and Oral GLP-1R

2This presentation includes forward- looking statements about, among other things, Pfizer’s Rare Disease and Internal

Medicine products and product candidates, including, among others, Giroctocogene fitelparvovec (SB-525),

Marstacimab and our investigational oral GLP -1RA agonist (PF -06882961), planned clinical studies, gene therapy and

their potential benefits, that are subject to substantial risks and uncertainties that could cause actual results to differ

materially from those expressed or implied by such statements. These statements are subject to risks, uncertainties and

other factors that may cause actual results to differ materially from past results, future plans and projected future

Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10- K for the fiscal year

ended December 31, 2019 and in our subsequent reports on Form 10- Q, including in the sections thereof captioned

“Risk Factors” and “Forward- Looking Information and Factors that May Affect Future Results,” as well as in our

subsequent reports on Form 8- K, all of which are filed with the US Securities and Exchange Commission (SEC) and

available at www.sec.gov and www.pfizer.com .

The forward- looking statements in this presentation speak only as of the original date of this presentation, and we

undertake no obligation to update or revise any of these statements.Disclaimer3

Introductory Remarks

Mikael Dolsten , M.D., Ph.D.

Chief Scientific Officer and President, Worldwide

Research, Development, and Medical​

Hemophilia A Gene Therapy